Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
Dennie MeijerPim J van LeeuwenMaarten L DonswijkThierry N BoellaardIvo G SchootsHendrik van der PoelHarry N HendrikseDaniela E Oprea-LagerAndré N VisPublished in: BJU international (2021)
Initial PSA value, biopsy GG ≥4, ≥rT3 disease on mpMRI and miN1 disease on PSMA PET were predictors of early biochemical progression after RARP. Identifying these patients with an increased risk of early biochemical progression after surgery may have major implications for patient counselling in radical treatment decisions and on patient selection for modern (neo-)adjuvant and systematic treatments.
Keyphrases
- prostate cancer
- positron emission tomography
- computed tomography
- pet ct
- magnetic resonance imaging
- pet imaging
- radical prostatectomy
- case report
- early stage
- type diabetes
- metabolic syndrome
- adipose tissue
- contrast enhanced
- hepatitis c virus
- skeletal muscle
- ultrasound guided
- insulin resistance
- hiv infected
- weight loss